Revive Therapeutics Stock Gross Profit
| RVVTF Stock | USD 0.01 0.0002 4.00% |
Revive Therapeutics fundamentals help investors to digest information that contributes to Revive Therapeutics' financial success or failures. It also enables traders to predict the movement of Revive OTC Stock. The fundamental analysis module provides a way to measure Revive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revive Therapeutics otc stock.
Revive |
Revive Therapeutics OTC Stock Gross Profit Analysis
Revive Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Revive Therapeutics reported 0.0 of gross profit. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Revive Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revive Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Revive Therapeutics could also be used in its relative valuation, which is a method of valuing Revive Therapeutics by comparing valuation metrics of similar companies.Revive Therapeutics is currently under evaluation in gross profit category among its peers.
Revive Fundamentals
| Return On Equity | -0.83 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | 32.12 M | |||
| Shares Outstanding | 353.56 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 2.42 % | |||
| Price To Earning | (4.10) X | |||
| Price To Book | 4.00 X | |||
| EBITDA | (17.74 M) | |||
| Net Income | (17.81 M) | |||
| Cash And Equivalents | 5.29 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 60 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 1.83 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (13.06 M) | |||
| Earnings Per Share | (0.06) X | |||
| Number Of Employees | 16 | |||
| Beta | -0.0535 | |||
| Market Capitalization | 36.1 M | |||
| Total Asset | 17.07 M | |||
| Retained Earnings | (4.38 M) | |||
| Working Capital | 132 K | |||
| Current Asset | 635 K | |||
| Current Liabilities | 503 K | |||
| Net Asset | 17.07 M |
About Revive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Revive OTC Stock
Revive Therapeutics financial ratios help investors to determine whether Revive OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.